Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)

Paul Coppo(Sorbonne Université), Marie Scully(University College Hospital), Xiaopu Zheng(Kansai Medical University), Michaela Larissa Lobo de Andrade(Hospital Universitário de Brasília), T Boechat(Hemorio), Raïda Bouzid(Inserm), Julio del Río-Garma(Complejo Hospitalario Universitario de Santiago), Bérangère S. Joly(Inserm), Ilaria Mancini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Eleni Gavriilaki(Aristotle University of Thessaloniki), Javier de la Rubia(Universitat de València), María Eva Mingot‐Castellano(Hospital Universitario Virgen del Rocío), Agnès Veyradier(Inserm), Bernhard Lämmle(Johannes Gutenberg University Mainz), Michaël Bubenheim(Centre Hospitalier Universitaire de Rouen), Shruti Chaturvedi(Johns Hopkins University), Spero R. Cataland(The Ohio State University), György Sinkovits(Semmelweis University), Y. Benhamou(Inserm), João Samuel de Holanda Farias(Hospital Erasto Gaertner), Flora Peyvandi(University of Milan), Masanori Matsumoto(Nara Medical University), Marshall Mazepa(University of Minnesota), Eduardo Flávio Oliveira Ribeiro(Hospital Universitário de Brasília), Paul Knoebl(Medical University of Vienna), Camila Masias(Baptist Health South Florida), Pasquale Agosti(University of Bari Aldo Moro), Linus A. Völker(University of Cologne), Lucas Kühne(University of Cologne), Katerina Pavenski(St. Michael's Hospital), Marienn Réti, Amjad Hmaid(University College London Hospitals NHS Foundation Trust), Cristina Pascual(Hospital General Universitario Gregorio Marañón), Christopher J. Patriquin(University Health Network), Paul Brinkkötter(University of Cologne), Matthew Stubbs(University College London Hospitals NHS Foundation Trust), Kazuya Sakai(Yokohama City University)
EClinicalMedicine
April 1, 2025
Cited by 41


Related Papers